REUVERS DANIEL L. 4

What Happened

• Daniel L. Reuvers, President and CEO of Neuronetics, received an award of 1,500,000 restricted stock units (RSUs) on March 23, 2026. The filing reports the RSUs at $0.00 per unit (total $0), reflecting an award/contingent grant rather than an open‑market purchase or sale.
• These RSUs are not immediately issued common shares; each RSU represents a contingent right to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-03-23. Transaction code: A (award/acquisition).
• Grant: 1,500,000 RSUs at $0.00 per unit (reported value $0 in the Form 4).
• Vesting: Award vests in three equal annual installments beginning March 23, 2027, subject to the reporting person’s continuous service through each vesting date (Footnote F1).
• Conversion: Each RSU converts to one share of common stock upon vesting (Footnote F2).
• Shares owned after the transaction: not disclosed in the provided filing.
• Timeliness: Form filed on the same date as the reported transaction period (no late filing indicated).

Context

• RSU grants are a common form of executive compensation and indicate potential future issuance of shares if vesting conditions are met; they do not represent an immediate market purchase or sale by the insider.
• Because RSUs depend on continued service and possibly other conditions, they should not be read as a direct bullish or bearish trade by the insider.